<DOC>
	<DOC>NCT01360840</DOC>
	<brief_summary>The primary objective of the trial is to evaluate the clinical anti-tumor activity of EMD 525797 administered as 1-hour intravenous infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC).</brief_summary>
	<brief_title>EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of the prostate (Gleason score) Bisphosphonate treatment Stable, ongoing adequate testosterone suppression proven by hypogonadal levels of testosterone (less than or equal to) &lt;= 50 nanogram per deciliter [ng/dL]) for subjects without surgical castration (luteinizing hormonereleasing hormone antagonists and agonists) Other protocol defined inclusion criteria could apply Prior chemotherapy, biologic therapy (targeted therapy), or any experimental therapy for mCRPC Chronic and ongoing treatment with opioids Acute pathologic fracture, spinal cord compression, or hypercalcemia at Screening Visceral metastasis, brain metastasis Radiotherapy to bone lesions and/or orthopedic surgery for pathologic fractures. Any kinds of major elective surgery within 30 days prior to trial treatment Other protocol defined exclusion criteria could apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Asymptomatic</keyword>
	<keyword>mildly symptomatic</keyword>
	<keyword>metastatic castrate-resistant prostate cancer</keyword>
	<keyword>mCRPC</keyword>
</DOC>